Table 1 Patient characteristics, tumor and treatment related factors. Differences between the HFRT and NFRT group were evaluated using Fisher’s exact test and the Wilcoxon rank sum test for categorical and continuous variables, respectively. Unknown values were excluded in these tests. KPS: Karnofsky performance status
Overall cohort | NFRT | HFRT | p-value | |||||
|---|---|---|---|---|---|---|---|---|
(n = 152) | (n = 38) | (n = 114) | ||||||
Age | Median, range | 59 | 11–81 | 57.5 | 28–75 | 60 | 11–81 | 0.553 |
Gender | Female | 60 | 39.5% | 15 | 39.5% | 45 | 39.5% | 1 |
Male | 92 | 60.5% | 23 | 60.5% | 69 | 60.5% | ||
Surgery extent | Complete resection | 50 | 32.9% | 8 | 21.1% | 42 | 36.8% | 0.0921 |
Subtotal resection | 52 | 34.2% | 16 | 42.1% | 36 | 31.6% | ||
Debulking | 11 | 7.2% | 5 | 13.2% | 6 | 5.3% | ||
Biopsy | 37 | 24.3% | 7 | 18.4% | 30 | 26.3% | ||
Unknown | 2 | 1.3% | 2 | 5.3% | 0 | 0% | ||
Mental status | Normal | 140 | 92.1% | 34 | 89.5% | 106 | 93.0% | 0.496 |
Impaired | 12 | 7.9% | 4 | 10.5% | 8 | 7.0% | ||
Neurological function | Normal | 109 | 71.7% | 29 | 76.3% | 80 | 70.2% | 0.537 |
Impaired | 43 | 28.3% | 9 | 23.7% | 34 | 29.8% | ||
MGMT-methylation | Yes | 47 | 30.9% | 12 | 31.6% | 35 | 30.7% | 0.803 |
No | 42 | 27.6% | 9 | 23.7% | 33 | 28.9% | ||
Unknown | 63 | 41.5% | 17 | 44.7% | 46 | 40.4% | ||
IDH-mutation | Yes | 6 | 3.9% | 1 | 2.6% | 5 | 4.4% | 1 |
No | 71 | 46.7% | 17 | 44.7% | 54 | 47.4% | ||
Unknown | 75 | 48.7% | 20 | 52.6% | 55 | 48.2% | ||
Secondary GBM | Yes | 12 | 7.9% | 4 | 10.5% | 8 | 7% | 0.486 |
No | 132 | 86.8% | 31 | 81.6% | 101 | 88.6% | ||
Unknown | 8 | 5.3% | 3 | 7.9% | 5 | 4.4% | ||
PTV [ccm] | ≤269 ccm | 66 | 43.4% | 15 | 39.5% | 51 | 44.7% | 1 |
> 269 ccm | 65 | 42.8% | 15 | 39.5% | 50 | 43.9% | ||
Unknown | 21 | 13.8% | 8 | 21.0% | 13 | 11.4% | ||
Temozolomide | No | 4 | 2.6% | 2 | 5.3% | 2 | 1.8% | 0.364 |
Concomitant | 23 | 15.1% | 4 | 10.5% | 19 | 16.7% | ||
Conc+sequen | 120 | 78.9% | 30 | 78.9% | 90 | 78.9% | ||
Sequential | 5 | 3.3% | 2 | 5.3% | 3 | 2.6% | ||
Concomitant steroids | No | 56 | 36.8% | 19 | 50.0% | 37 | 32.5% | 0.0714 |
Yes | 77 | 50.7% | 15 | 39.5% | 62 | 54.4% | ||
Unknown | 19 | 12.5% | 4 | 10.5% | 15 | 13.2% | ||
Radiotherapy completed | Yes | 145 | 95.4% | 37 | 97.4% | 108 | 94.7% | 0.681 |
No | 7 | 4.6% | 1 | 2.6% | 6 | 5.3% | ||
Additional Boost | Yes | 27 | 17.8% | 5 | 13.2% | 22 | 19.3% | 0.470 |
No | 125 | 82.2% | 33 | 86.8% | 92 | 80.7% | ||
Salvage | No | 55 | 36.2 | 8 | 21.1% | 47 | 41.2% | 0.0337 |
Yes | 68 | 44.7% | 22 | 57.9% | 46 | 40.4% | ||
Unknown | 29 | 19.1% | 8 | 21.1% | 21 | 18.4% | ||
KPS at RT start | < 70 | 18 | 11.8% | 1 | 2.6% | 17 | 14.9% | 0.119 |
70–80 | 64 | 42.1% | 18 | 47.4% | 46 | 40.4% | ||
> 80 | 70 | 46.1% | 19 | 50.0% | 51 | 44.7% | ||
Treatment period | 2004–2008 | 5 | 3.3% | 1 | 2.6% | 4 | 3.5% | 0.779 |
2009–2013 | 67 | 44.1% | 19 | 50.0% | 48 | 42.1% | ||
2014–2018 | 80 | 52.6% | 18 | 47.4% | 62 | 54.3% | ||
In- /outpatient | Inpatient | 14 | 9.2% | 2 | 5.3% | 12 | 10.5% | 0.126 |
Outpatient | 135 | 88.8% | 34 | 89.5% | 101 | 88.6% | ||
Unknown | 3 | 2% | 2 | 5.3% | 1 | 0.9% | ||
Tumor treating fields | No | 138 | 90.8% | 35 | 92.1% | 103 | 90.4% | 1 |
Yes | 14 | 9.2% | 3 | 7.9% | 11 | 9.6% | ||